MedPath

Microtransponder, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Breakthrough Clinical Trial Shows Vagus Nerve Stimulation Significantly Improves Spinal Cord Injury Recovery

• UT Dallas researchers demonstrated unprecedented recovery rates for spinal cord injuries using closed-loop vagus nerve stimulation (CLV) combined with individualized rehabilitation. • The clinical trial showed significant improvements in arm and hand function among participants with chronic cervical spinal cord injuries, regardless of age or time since injury. • Following these promising results, researchers are advancing to a pivotal Phase 3 trial with 70 participants across multiple U.S. institutions, potentially leading to FDA approval.

Vivistim VNS Therapy Shows Promising Real-World Outcomes in Chronic Stroke Recovery

• Real-world data from 25 chronic stroke patients demonstrates significant improvement in upper extremity function with Vivistim paired VNS therapy, showing mean FMA-UE score increase of 9.53 points. • The FDA-approved breakthrough device proves effective even in patients averaging 3.6 years post-stroke, with successful outcomes in 22 of 25 patients completing the six-week protocol. • Microtransponder's Vivistim therapy has gained significant adoption, now utilized by 20% of Joint Commission Comprehensive Stroke Centers and 50% of top neuro and spine programs.
© Copyright 2025. All Rights Reserved by MedPath